Filing Details

Accession Number:
0000950170-23-073585
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-28 16:05:12
Reporting Period:
2023-12-26
Accepted Time:
2023-12-28 16:05:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1274792 Merrimack Pharmaceuticals Inc MACK Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1450414 Western Standard Partners Lp 5900 Wilshire Boulevard, Suite 650
Los Angeles CA 90036
No No No No
1517666 Western Standard Llc 5900 Wilshire Boulevard, Suite 650
Los Angeles CA 90036
No No No No
1517667 Eric Andersen 5900 Wilshire Boulevard, Suite 650
Los Angeles CA 90036
No No No No
1544857 Western Standard Partners Qp, L.p. 5900 Wilshire Boulevard, Suite 650
Los Angeles CA 90036
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-26 48,693 $13.15 533,151 No 4 P Indirect See footnote
Common Stock Acquisiton 2023-12-28 857 $13.35 534,008 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.12 to $13.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. The shares are directly held by WSP QP. The general partner of the Funds is Western Standard. The managing member of Western Standard and the portfolio manager to the Funds is Mr. Andersen. Each of Western Standard and Mr. Andersen disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.34 to $13.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.